Literature DB >> 19772423

Early recurrence of papillary and follicular thyroid carcinoma predicts a worse outcome.

Jen-Der Lin1, Chuen Hsueh, Tzu-Chieh Chao.   

Abstract

BACKGROUND: The occurrence of recurrent papillary and follicular thyroid carcinomas is not unusual. Numerous studies have reported the association between risk factors of initial surgery and recurrence of papillary and follicular thyroid carcinomas. However, we do not have sufficient data to analyze the time of postoperative recurrence associated with therapeutic results and cancer mortality. We hypothesized that an early recurrence of papillary and follicular thyroid cancers implies a rapid growth of cancer resulting in high mortality rate.
METHODS: We conducted a retrospective study in a medical center in northern Taiwan. The investigation included 2148 cases of papillary and follicular thyroid carcinoma, including 325 recurrent cases during the period between 1977 and 2006. The studied cases were categorized into early or late recurrence groups. Cases with an early recurrence were defined as those in which recurrence occurred in the first year following thyroid surgery.
RESULTS: Tumor size, radioactive iodide treatment, multifocality, and tumor-node metastasis stage were independent predictors of recurrence. After a mean follow-up of 8.7 +/- 0.1 years, death due to thyroid cancer was observed to occur in 105 (32.3%) recurrent cases. Among the 325 recurrent cases, early recurrence was detected in 185 cases, and late recurrence was detected in 140 cases. Early recurrence was mostly observed in older male patients; a high mortality rate was associated with these cases. Distant metastases were observed in about 80% of the cases in the early recurrence group, whereas localized metastases in the neck region were observed in more than half the cases in the late recurrence group. The percentage of patients with a non-disease-free status and distant metastases in the early recurrence group was higher than that in the late recurrence group. The 10-year disease-specific survival rates were 52.5% and 85.1% for the early and late recurrence groups, respectively.
CONCLUSIONS: Early recurrent papillary and follicular thyroid carcinomas are associated with high mortalities. Tumor size and multifocality deserve consideration as indicators of recurrence. Therefore, patients whose primary follicular or papillary thyroid carcinoma has features associated with early recurrence should probably receive more aggressive initial treatment.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19772423     DOI: 10.1089/thy.2009.0133

Source DB:  PubMed          Journal:  Thyroid        ISSN: 1050-7256            Impact factor:   6.568


  12 in total

1.  Recurrent differentiated thyroid cancer: to cut or burn.

Authors:  Roberto Cirocchi; Stefano Trastulli; Alessandro Sanguinetti; Lorenzo Cattorini; Piero Covarelli; Domenico Giannotti; Giorgio Di Rocco; Fabio Rondelli; Francesco Barberini; Carlo Boselli; Alberto Santoro; Nino Gullà; Adriano Redler; Nicola Avenia
Journal:  World J Surg Oncol       Date:  2011-08-12       Impact factor: 2.754

2.  Prognosis of patients with papillary thyroid carcinoma showing postoperative recurrence to the central neck.

Authors:  Yasuhiro Ito; Takuya Higashiyama; Yuuki Takamura; Kaoru Kobayashi; Akihiro Miya; Akira Miyauchi
Journal:  World J Surg       Date:  2011-04       Impact factor: 3.352

3.  Long-term results of surgery for papillary thyroid carcinoma with local recurrence.

Authors:  Hiroki Uchida; Tsuneo Imai; Toyone Kikumori; Hironori Hayashi; Shigenori Sato; Sumiyo Noda; Ai Idota; Tetsuya Kiuchi
Journal:  Surg Today       Date:  2012-10-10       Impact factor: 2.549

4.  Prognostic importance of baseline neutrophil to lymphocyte ratio in patients with advanced papillary thyroid carcinomas.

Authors:  Ju-Yeon Kim; Taejin Park; Sang-Ho Jeong; Chi-Young Jeong; Young-Tae Ju; Young-Joon Lee; Soon-Chan Hong; Woo-Song Ha; Sang-Kyung Choi; Eun Jung Jung
Journal:  Endocrine       Date:  2013-11-23       Impact factor: 3.633

5.  Dual-energy computed tomography could reliably differentiate metastatic from non-metastatic lymph nodes of less than 0.5 cm in patients with papillary thyroid carcinoma.

Authors:  Ying Zou; Meizhu Zheng; Ziyu Qi; Yu Guo; Xiaodong Ji; Lixiang Huang; Yan Gong; Xiudi Lu; Guolin Ma; Shuang Xia
Journal:  Quant Imaging Med Surg       Date:  2021-04

6.  Combined analysis of circulating epithelial cells and serum thyroglobulin for distinguishing disease status of the patients with papillary thyroid carcinoma.

Authors:  Hung-Chih Lin; Miaw-Jene Liou; Hsung-Ling Hsu; Jason Chia-Hsun Hsieh; Yi-An Chen; Ching-Ping Tseng; Jen Der Lin
Journal:  Oncotarget       Date:  2016-03-29

7.  An Ep-ICD based index is a marker of aggressiveness and poor prognosis in thyroid carcinoma.

Authors:  Helen C-H He; Lawrence Kashat; Ipshita Kak; Tada Kunavisarut; Raefe Gundelach; Dae Kim; Anthony K-C So; Christina MacMillan; Jeremy L Freeman; Ranju Ralhan; Paul G Walfish
Journal:  PLoS One       Date:  2012-09-25       Impact factor: 3.240

8.  Circulating epithelial cell counts for monitoring the therapeutic outcome of patients with papillary thyroid carcinoma.

Authors:  Ching-Ping Tseng; Kong-Kit Leong; Miaw-Jene Liou; Hsueh-Ling Hsu; Hung-Chih Lin; Yi-An Chen; Jen-Der Lin
Journal:  Oncotarget       Date:  2017-08-24

9.  Long-term therapeutic outcomes of papillary thyroid carcinoma with concomitant hyperparathyroidism: A single center case-control study.

Authors:  Chih-Yiu Tsai; Szu-Tah Chen; Chuen Hsueh; Yann-Sheng Lin; Jen-Der Lin
Journal:  Biomed J       Date:  2020-02-27       Impact factor: 4.910

10.  Microscopic Positive Tumor Margin Increases Risk for Disease Persistence but Not Recurrence in Patients with Stage T1-T2 Differentiated Thyroid Cancer.

Authors:  Olfat Kamel Hasan; Sarah De Brabandere; Irina Rachinsky; David Laidley; Danielle MacNeil; Stan Van Uum
Journal:  J Thyroid Res       Date:  2020-01-10
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.